Form 4 for EDSA Edesa Biotech, Inc.
Accepted 2022-07-05 00:00:00 ET · period of report 2022-06-30 · accession 0001654954-22-009259 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-05 | 2022-06-30 | EDSA | Pardeep Nijhawan Medicine Professional Corp | CEO, Dir, 10% | P - Purchase | $1.60 | +20.0K | 594.8K | +3% | +$32.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-06-30 | P | A | 20,000 | $1.60 | 594,812 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $1.52 to $1.6622. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |